The expert panel concludes with thoughts on unmet needs and future perspectives on the treatment of patients with EGFR-mutated non–small cell lung cancer.
Dato-DXd Earns FDA Accelerated Approval in Pretreated EGFR-Mutated mNSCLC
The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.
Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
FDA Approves Taletrectinib in ROS1+ NSCLC
Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.
Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC
Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.
Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC
Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.